Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 2/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12199014 | 0.96 | GPR119 (0.46) | GPR119CHRM1CHRM2CHRM3EPHX1 | |
| SCHEMBL16281291 | 0.83 | GPR119 (0.38) | GPR119CHRM1CHRM2CHRM3EPHX1 | |
| SCHEMBL12086347 | 0.81 | EPHX1 (0.40) | GPR119CHRM1CHRM2CHRM3EPHX1 | |
| SCHEMBL12084009 | 0.81 | CHRM1 (0.45) | GPR119CHRM1CHRM2CHRM3EPHX1 | |
| SCHEMBL12988783 | 0.81 | GPR119 (0.38) | GPR119CHRM1CHRM2CHRM3EPHX1 | |
| SCHEMBL31512330 | 0.79 | NAAA (0.41) | GPR119EPHX1BCHENAAACYP19A1 | |
| SCHEMBL31512334 | 0.79 | NAAA (0.41) | GPR119EPHX1BCHENAAACYP19A1 | |
| SCHEMBL31512362 | 0.79 | NAAA (0.41) | GPR119EPHX1BCHENAAACYP19A1 | |
| SCHEMBL31512354 | 0.79 | NAAA (0.41) | GPR119EPHX1BCHENAAACYP19A1 | |
| SCHEMBL13034559 | 0.79 | JAK3 (0.38) | GPR119CHRM1CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281476-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| EP-2364705-A2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281476-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | GPR119 77/4885CHRM1 6/4885CHRM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.